Home » Global Fabry Disease Therapeutic Market

Global Fabry Disease Therapeutic Market – Growth, Share, Opportunities & Competitive Analysis, 2016 – 2024

Price: $4999

Published: | Report ID: 12266 | Report Format : PDF

Market Insights

Fabry disease is a rare, X-linked, inherited disorder of lipid metabolism resulting from the deficient activity of the enzyme alpha-galactosidase-A. This enzyme is normally responsible for the breakdown of globotriaosylceramide, which results in abnormal deposits of a particular fatty substance in the walls of the blood vessels throughout the body. Characteristic features of Fabry disease include episodes of pain, cloudiness of the front part of the eye, clusters of small and dark red spots on the skin, and hearing loss.

The disease also involves life-threatening complications such as heart attack, kidney damage, and stroke. There are two types of Fabry disease: type 1 classic phenotype and type 2 later-onset phenotype. According to the National Organization for Rare Disorders (NORD), the incidence of type 1 classic phenotype is about 1 in 40,000 in males but varies with demography and race, ranging from about 1 in 18,000 to 1 in 95,000. The incidence of type 2 later-onset in males varies by ethnicity, demography, and race but is at least ten times more frequent than that of type 1 classic phenotype in the same region, ethnic group, or race.

There is no cure for Fabry’s disease, but medications are available to treat the condition. Enzyme Replacement Therapy (ERT) is used for treatment. Currently, only two ERT preparations, such as Replagal and Fabrazyme, are available on the market that is administered by intravenous infusion. In the USA, only Sanofi-Genzyme’s agalsidase beta (Fabrazyme) is FDA-approved. Shire’s Agalsidase alfa (Replagal) is approved in Europe and many other countries but not in the United States.

Fabrazyme and Replagal are administered every two weeks for a lifetime or until another appropriate medication become available. ERT is an extremely expensive treatment. Other treatments may also involve medications to reduce symptoms, such as pain medications, medications to treat stomach hyperactivity, blood thinners, and medications to manage arrhythmias and other heart disorders.

Key drivers for the global Fabry disease therapeutic market include extensive investigations and the adoption of advanced technology in research and development. Various therapeutic products, such as SMP-536, PRX-102, AT-1001, GC-1119, SAR-402671, PRX-102, and others, are in clinical trial studies. Fabry disease has been designated an ICD-10-CM code by the government and private insurance that can be used to indicate a diagnosis for reimbursement purposes, which would further drive the market. The disorder’s rare incidence rate (1:40,000) is a major impediment to growth in the global market for Fabry disease.

Companies such as Genzyme-Sanofi and Shire are the major players in the market, as only these companies have approved drugs on the market currently. Major players involved in the development of new medications include Amicus Therapeutics, Shire, Genzyme-Sanofi, Protalix, Sanofi-Aventis LLC, Novartis Pharmaceuticals, Pfizer, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., AbbVie Inc., Takeda Pharmaceutical Co. Ltd., and Green Cross Corp.

The Global Fabry Disease Therapeutic Market Is Divided Into the Following Subsegments:

  • Global Fabry Disease Drug Market Revenue (USD Mn) By drug type, 2016–2024
  • enzyme replacement therapy
  • Alternative therapies
  • Global Fabry Disease Drug Market Revenue (USD Mn), By Geography, 2016-2024
  • North America
  • US
  • Canada
  • Europe
  • UK
  • Germany
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Rest of APAC
  • Latin America
  • Middle East and Africa

Key players identified for the global Fabry disease therapeutic market include:

Amicus Therapeutics, Shire, Genzyme-Sanofi, Protalix, Sanofi-Aventis LLC, Novartis Pharmaceuticals, Pfizer, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Merc & Co., AbbVie Inc., Takeda Pharmaceutical Co. Ltd., Green Cross Corp.

This report offers:

  • An overview of the global markets for Fabry disease therapeutics
  • Market trends assessment for the period 2014-2024, including historical data for 2014 and 2015 and projections through 2024, with respective CAGRs from 2016 to 2024.
  • Qualitative assessment tools such as market drivers, challenges, and future prospects
  • Market competition examination tools such as market share analysis and fractal map evaluation
  • Focus on each level of market segmentation based on product approvals, launches, and current and anticipated market dynamics.
  • A general overview of the industry structure

Frequently Asked Questions

What is the size of Fabry Disease Therapeutic Market?

The market for Fabry Disease Therapeutic Market is expected to reach US$ XX Bn By 2024.

What is the Fabry Disease Therapeutic Market CAGR?

The Fabry Disease Therapeutic Market is expected to see significant CAGR growth over the coming years, at 13%.

What is the Forecast period considered for Fabry Disease Therapeutic Market?

The report is forecasted from 2016-2024.

What is the base year considered for Fabry Disease Therapeutic Market?

The base year of this report is 2015.

Who are the major players in this market?

Shire, Genzyme-Sanofi, Protalix, Sanofi-Aventis LLC, Novartis Pharmaceuticals, Pfizer, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Merc & Co., AbbVie Inc., Takeda Pharmaceutical Co. Ltd., Green Cross Corp are some of the major players in the global market.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

Published:
Report ID: 33712

Tracheitis Treatment Market

Published:
Report ID: 33694

Neuralgia Treatment Market

Published:
Report ID: 33681

Clostridioides Difficile (C. diff) Treatment Market

Published:
Report ID: 33667

Sphingosine-1-Receptor Modulators Drugs Market

Published:
Report ID: 33649

Neuromyelitis Optica Therapy Market

Published:
Report ID: 33583

Pediatric Bladder Treatment Market

Published:
Report ID: 33540

Neurotrophic Keratitis Treatment Market

Published:
Report ID: 33425

Precision Medicine Market

Published:
Report ID: 11123

Eosinophilic Pneumonia Treatment Market

Published:
Report ID: 5486

Myelodysplastic Syndrome Market

Published:
Report ID: 32821

US Retail Pharmacy Market

Published:
Report ID: 32801

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN